e-therapeutics plc is a specialist in computational drug discovery with a focus on developing RNAi therapeutics.

Based in London, UK, the Company integrates computational power and biology to accelerate the discovery of life-transforming medicines. e-therapeutics has developed and validated a powerful, disease and modality agnostic computational approach to drug discovery, leveraging its industry-leading expertise in network biology to fully capture and interrogate human disease complexity.

The Company’s multi-disciplinary team builds computational models of biological functions to transform the search for new medicines, interventions, mechanisms and genetic support. Its biology-led in silico laboratory enables rapid hypothesis generation and phenotypic screening of millions of compounds leading to 100-1,000x higher hit rates in the wet lab and successful mode of action elucidation. Novel targets can also be identified, prioritised and assessed. Harnessing internal target gene discoveries, e-therapeutics is currently building an in-house pipeline of RNAi based medicines, using its proprietary GalNAc-siRNA technology.

e-therapeutics has deployed and validated its disease-agnostic computational drug discovery platform both in house and with partners, including Novo Nordisk, Galapagos NV and a US-based, top five pharmaceutical company.

Details of e-therapeutics’ Board of Directors, including biographical information, are available here.

A description of the responsibilities of the Directors and details of Board Committees and their responsibilities are available here.

The Company’s articles of association are available here.

Country of incorporation and main country of operation
e-therapeutics plc is incorporated in England and Wales. Its main country of operation is the UK.

Details of the number of AIM securities in issue, the percentage of AIM securities that are not in public hands and the identity and percentage holdings of its significant shareholders are available here.

Copies of the Company’s annual reports and interim financial statements may be accessed here.

Details of the Company’s corporate governance arrangements are available here.

The Company is subject to the UK City Code on Takeovers and Mergers.

Details of the Company’s nominated advisor and other key advisors may be found here.

Last updated: 05 January 2024